Bristol Myers Squibb Expects FY23 Revenues To Low Single-Digit Decline (Vs. Prior Increase Of 2%) , With Adjusted EPS Of $7.35-$7.65 Down From Previous Guidance Of $7.95-$8.25 Vs. Consensus Of $7.99, Due To Lower Revenues for Revlimid, Pomalyst
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb has revised its FY23 revenue forecast to a low single-digit decline, compared to a previous increase of 2%. The adjusted EPS is now expected to be $7.35-$7.65, down from the previous guidance of $7.95-$8.25. This is due to lower revenues for Revlimid and Pomalyst.
July 27, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bristol Myers Squibb's revised FY23 revenue and EPS forecasts are lower than previously expected, due to reduced revenues for Revlimid and Pomalyst.
Bristol Myers Squibb has lowered its FY23 revenue and EPS forecasts due to lower revenues for Revlimid and Pomalyst. This could negatively impact the company's stock price in the short term as it indicates potential financial difficulties.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100